In this article, the author discusses the development of drug for bioactive lipid targets. The author states that the earliest pharmaceutically aimed bioactive lipid pathway was the arachidonic acid-deduced prostaglandin pathway. The author says that new drugs had to be able to bring pathological procedures back into physiological balance without themselves harming the body.